Stock PFE PFIZER, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 01:31:36 27/04/2024 am IST 		5-day change 1st Jan Change
25.4 USD +0.55% Intraday chart for Pfizer, Inc. -2.31% -11.77%
26/04 S&P 500 Posts First Weekly Gain Since March as Tech, Consumer Discretionary Lead Rise on Better-Than-Expected Earnings MT
26/04 Sector Update: Health Care Stocks Edge Higher Late Afternoon MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 2,16,827 2,04,605 3,31,440 2,87,626 1,62,560 1,43,829 - -
Enterprise Value (EV) 1 2,59,147 2,32,220 3,38,807 3,00,723 2,21,758 1,90,866 1,85,740 1,79,763
P/E ratio 13.7 x 21.5 x 15.3 x 9.37 x 77.8 x 18.7 x 13.6 x 12.4 x
Yield 3.68% 4.13% 2.64% 3.14% 5.73% 6.68% 6.85% 6.94%
Capitalization / Revenue 4.19 x 4.88 x 4.08 x 2.87 x 2.78 x 2.4 x 2.3 x 2.27 x
EV / Revenue 5.01 x 5.54 x 4.17 x 3 x 3.79 x 3.18 x 2.97 x 2.84 x
EV / EBITDA 12.3 x 13 x 13.3 x 7.1 x 14.2 x 9.64 x 8.2 x 7.63 x
EV / FCF 24.9 x 19.1 x 11.3 x 11.6 x 46.3 x 19.6 x 12.6 x 11.1 x
FCF Yield 4.02% 5.23% 8.82% 8.66% 2.16% 5.1% 7.92% 9.01%
Price to Book 3.43 x 3.24 x 4.3 x 3 x 1.83 x 1.65 x 1.64 x 1.62 x
Nbr of stocks (in thousands) 55,34,122 55,58,397 56,12,867 56,13,315 56,46,413 56,62,541 - -
Reference price 2 39.18 36.81 59.05 51.24 28.79 25.40 25.40 25.40
Announcement Date 28/01/20 02/02/21 08/02/22 31/01/23 30/01/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 51,750 41,908 81,288 1,00,330 58,496 59,955 62,567 63,284
EBITDA 1 21,097 17,801 25,426 42,336 15,590 19,802 22,661 23,561
EBIT 1 19,420 13,024 20,235 37,272 9,300 16,364 19,064 19,964
Operating Margin 37.53% 31.08% 24.89% 37.15% 15.9% 27.29% 30.47% 31.55%
Earnings before Tax (EBT) 1 17,682 7,497 24,311 34,729 1,058 9,561 13,702 12,097
Net income 1 16,273 9,616 21,979 31,372 2,119 6,746 9,289 10,111
Net margin 31.45% 22.95% 27.04% 31.27% 3.62% 11.25% 14.85% 15.98%
EPS 2 2.870 1.710 3.850 5.470 0.3700 1.362 1.874 2.054
Free Cash Flow 1 10,412 12,151 29,869 26,031 4,793 9,742 14,711 16,190
FCF margin 20.12% 28.99% 36.74% 25.95% 8.19% 16.25% 23.51% 25.58%
FCF Conversion (EBITDA) 49.35% 68.26% 117.47% 61.49% 30.74% 49.2% 64.92% 68.71%
FCF Conversion (Net income) 63.98% 126.36% 135.9% 82.98% 226.19% 144.41% 158.38% 160.13%
Dividend per Share 2 1.440 1.520 1.560 1.610 1.650 1.696 1.739 1.763
Announcement Date 28/01/20 02/02/21 08/02/22 31/01/23 30/01/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 24,094 23,838 25,661 27,742 22,638 24,290 18,282 12,734 13,232 14,249 13,923 13,125 15,077 17,812 15,680
EBITDA 1 9,876 4,403 11,135 13,583 10,325 6,772 7,857 4,925 -1,244 1,340 4,403 4,126 5,359 4,754 -
EBIT 1 8,516 3,126 9,948 12,408 9,142 5,253 6,370 3,319 -1,625 -330 3,667 3,343 4,305 4,999 -
Operating Margin 35.34% 13.11% 38.77% 44.73% 40.38% 21.63% 34.84% 26.06% -12.28% -2.32% 26.34% 25.47% 28.55% 28.07% -
Earnings before Tax (EBT) 1 - - 9,050 - - 5,231 - - -3,352 -4,129 2,992 2,061 2,651 3,182 -
Net income 1 8,146 3,393 7,864 9,906 8,608 4,995 5,543 2,327 -2,382 -3,369 1,951 1,265 2,156 3,135 -
Net margin 33.81% 14.23% 30.65% 35.71% 38.02% 20.56% 30.32% 18.27% -18% -23.64% 14.01% 9.64% 14.3% 17.6% -
EPS 2 1.420 0.5900 1.370 1.730 1.510 0.8700 0.9700 0.4100 -0.4200 -0.6000 0.3416 0.2331 0.4250 0.5533 -
Dividend per Share 2 0.3900 0.3900 0.4000 0.4000 0.4000 0.4100 0.4100 0.4100 0.4100 0.4200 0.4109 0.4109 0.4109 0.4109 0.4220
Announcement Date 02/11/21 08/02/22 03/05/22 28/07/22 01/11/22 31/01/23 02/05/23 01/08/23 31/10/23 30/01/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 42,320 27,615 7,367 13,097 59,198 47,037 41,911 35,934
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.006 x 1.551 x 0.2897 x 0.3094 x 3.797 x 2.375 x 1.849 x 1.525 x
Free Cash Flow 1 10,412 12,151 29,869 26,031 4,793 9,742 14,711 16,190
ROE (net income / shareholders' equity) 25.7% 15.2% 31.3% 43.5% 11.4% 12.4% 15.5% 15.9%
ROA (Net income/ Total Assets) 9.96% 5.98% 13.1% 19.9% 4.96% 4.39% 5.8% 6.43%
Assets 1 1,63,456 1,60,910 1,67,853 1,57,490 42,750 1,53,543 1,60,234 1,57,232
Book Value Per Share 2 11.40 11.40 13.70 17.10 15.80 15.30 15.50 15.70
Cash Flow per Share 2 2.220 2.560 5.710 5.110 1.520 2.800 3.630 3.750
Capex 1 2,176 2,252 2,711 3,236 3,907 2,897 2,912 2,937
Capex / Sales 4.2% 5.37% 3.34% 3.23% 6.68% 4.83% 4.65% 4.64%
Announcement Date 28/01/20 02/02/21 08/02/22 31/01/23 30/01/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Pfizer, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
25.4 USD
Average target price
31.62 USD
Spread / Average Target
+24.49%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
PFIZER, INC. Stock Pfizer, Inc.
-11.77% 144B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. PFE Stock
  4. Financials Pfizer, Inc.